BRCA2 and familial pancreatic carcinoma: It is possibly that the future development of diagnosing the predisposition of familial pancreatic cancer is to evaluate genomic modifications; in fact, it has been recently reported that prevalence of mutations among familial pancreatic cancer probands was 1.2 % for BRCA1, 3.7 % for BRCA2, 0.6 % for PALB2, and 2.5 % for CDKN2A [20].